Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase

Molecular and Biochemical Parasitology

Volumn 103, Issue 1, 1999, Pages 15-23

  Darling, John A ^a   Sullivan Jr , William J ^a   Carter, Darrick ^b   Ullman, Buddy ^b   Roos, David S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Apicomplexan parasites; Enzyme kinetics; Nucleoside metabolism; Protein purification; Purine salvage

Indexed keywords

ADENOSINE KINASE; NITROBENZYLTHIOINOSINE; RECOMBINANT ENZYME; TUBERCIDIN; VIDARABINE;

ARTICLE; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME PURIFICATION; GENE EXPRESSION; MUTANT; PRIORITY JOURNAL; TOXOPLASMA GONDII;

ADENOSINE KINASE; ANIMALS; ANTIPROTOZOAL AGENTS; DNA, COMPLEMENTARY; DNA, PROTOZOAN; ENZYME INHIBITORS; ESCHERICHIA COLI; GENE EXPRESSION; KINETICS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TOXOPLASMA;

FELIS CATUS; TOXOPLASMA GONDII;

EID: 0032868347     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(99)00109-7     Document Type: Article

References (34)

1. Wilson C.B., Remington J.S. What can be done to prevent congenital toxoplasmosis? Am. J. Obstet. Gynecol. 138:1980;357-363.
2. McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72.
3. Luft B.J., Brooks R.G., Conley F.K., McCabe R.E., Remington J.S. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. J. Am. Med. Assoc. 252:1984;913-917.
4. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:1992;211-222.
5. Brooks R.G., Remington J.S., Luft B.J. Drugs used in the treatment of toxoplasmosis. Antimicrob. Agents Annu. 2:1987;297-306.
6. Haverkos H.W. Assessment of therapy for toxoplasmic encephalitis. Am. J. Med. 82:1987;907-914.
7. Leport C., Raffi F., Katlama C., Regnier B., Saimot A.G., Marche C., Vedrenne C., Vilde J.L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfonamide combination in 35 patients with the acquired immunodeficiency syndrome. Am. J. Med. 84:1988;94-100.
8. Laughon B.E., Allaudeen H.S., Becker J.M. et al. Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS. J. Infect. Dis. 164:1991;244-251.
9. Araujo F.G., Remington J.S. Recent advances in the search for new drugs for treatment of toxoplasmosis. Int. J. Antimicr. Agents. 1:1992;153-164.
10. Lane H.C., Laughon B.E., Falloon J., Kovacs J.A., Davey R.T.Jr., Polis M.A., Masur H. Recent advances in the management of AIDS-related opportunistic infections. Ann. Int. Med. 120:1994;945-955.
11. Perotto J., Keister D.B., Gelderman A.H. Incorporation of precursors into Toxoplasma DNA. J. Protozool. 18:1971;470-473.
12. Schwartzman J.D., Pfefferkorn E.R. Toxoplasma gondii: Purine synthesis salvage in mutant host cells and parasites. Exp. Parasitol. 53:1982;77-86.
13. Krug E.C., Marr J.J., Berens R.L. Purine metabolism in Toxoplasma gondii. J. Biol. Chem. 264:1989;10601-10607.
14. Ullman B., Carter D. Hypoxanthine-guanine phosphoribosyltransferase as a therapeutic target in protozoal infections. Infect. Agents Dis. 4:1995;29-40.
15. Gallerano R.H., Sosa R.R., Marr J.J. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am. J. Trop. Med. Hyg. 43:1990;159-166.
16. Martinez S., Marr J.J. Allopurinol in the treatment of American cutaneous leishmaniasis. N. Engl. J. Med. 326:1992;741-744.
17. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: Handman JG, Limbird LE, Molinof PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996. p. 1247-1257.
18. Pfefferkorn E.R., Borotz S.E. Toxoplasma gondii: Characterization of a mutant resistant to 6-thioxanthine. Exp. Parasitol. 79:1994;374-382.
19. Pfefferkorn E.R., Pfefferkorn L.C. Arabinosyl nucleotides inhibit Toxoplasma gondii and allow the selection of resistant mutants. J. Parasitol. 62:1976;993-999.
20. Pfefferkorn E.R., Pfefferkorn L.C. The biochemical basis for resistance to adenine arabinoside in a mutant of Toxoplasma gondii. J. Parasitol. 64:1978;486-492.
21. Donald R.G.K., Carter D., Ullman B., Roos D.S. Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. J. Biol. Chem. 271:1996;14010-14018.
22. Sullivan WJ, Jr. Molecular Genetic Dissection of Purine Metabolism and Drug Resistance in the Protozoan Parasite Toxoplasma gondii. PhD dissertation, Department of Biology, University of Pennsylvania, 1998.
23. Iltzsch M.H., Uber S.S., Ankersley K.O., el Kouni M.H. Structure-activity relationship for the binding of nucleoside ligands to adenosine kinase from Toxoplasma gondii. Biochem. Pharmacol. 10:1995;1501-1512.
24. Craig S.P., Yuan L., Kuntz D.A., McKerrow J.H., Wang C.C. High level expression in E. coli of soluble, enzymatically active schistosomal hypoxanthine-guanine phosphoribosyltransferase and trypanosomal ornithine decarboxylase. Proc. Natl. Acad. Sci. USA. 88:1991;2500-2504.
25. Allen T.E., Ullman B. Cloning and expression of the hypoxanthine-guanine phosphoribosyltransferase gene from Trypanosoma brucei. Nucl. Acids Res. 21:1994;5431-5438.
26. De Jong J.W., Keijzer E., Uitendaal M.P., Harmsen E. Further purification of adenosine kinase from rat heart using affinity and ion-exchange chromatography. Anal. Biochem. 101:1979;407-412.
27. Roos D.S., Donald R.G.K., Morrissette N.S., Moulton A.L.C. Molecular tools for the genetic dissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol. 45:1994;23-65.
28. Spychala J., Datta N.S., Wakabayashi K., Fox I.H., Gribbon T., Mitchell B.S. Cloning of human adenosine kinase cDNA: Sequence similarity to microbial ribokinases and fructokinases. Proc. Nat. Acad. Sci. USA. 93:1996;1232-1237.
29. Hurley M.C., Lin B., Fox I.H. Regulation of deoxyadenosine and nucleoside analog phosphorylation by human placental adenosine kinase. J. Biol. Chem. 260:1985;15675-15681.
30. Sullivan WJJr, Chiang CW, Wilson CM, Nagnib fNM, el Kuomi MH, Donald RGK, Roos DS. Insertional tagging of at least two loci associatedwith resistance to adenine arabinoside in Toxoplasma gondii, and cloning of the adenosine kinase locus. Mol Biochem Parasitol 1999;103:1-14.
31. Mathews I.I., Erion M.D., Ealick S.E. Structure of human adenosine kinase at 1.5 Å resolution. Biochemistry. 37:1998;15607-15620.
32. Chang C.-H., Brockman R.W., Bennett L.L. Jr. Adenosine kinase from L1210 cells: purification and some properties of the enzyme. J. Biol. Chem. 255:1980;2366-2371.
33. Miller R.L., Adamczyk D.L., Miller W.H. et al. Adenosine kinase from rabbit liver II. Substrate and inhibitor specificity. J. Biol. Chem. 254:1979;2346-2352.
34. Bennet L.L.Jr., Hill D.L. Structural requirements for activity of nucleosides as substrates for adenosine kinase: Orientation of substituents on the pentofuranosyl ring. Mol. Pharmacol. 11:1975;803-808.